FOR IMMEDIATE RELEASE ORLANDO, FL – October 24, 2024 – Hesperos, a leader in human-on-a-chip technology, has announced a breakthrough with the development of a human induced pluripotent stem cell (iPSC)-derived model of peripheral myelination. Published … Read More
Hesperos Appoints L. Florin as CEO “I am excited to join Hesperos during this period of explosive growth […and] lead this exceptional team as we continue delivering breakthrough solutions that advance drug discovery and benefit patients … Read More
PRESS RELEASE: Hesperos announces its Human-on-a-Chip® technology supported Dianthus Therapeutics’ FDA submission for a Phase II trial of DNTH103 for generalized myasthenia gravis.
ORLANDO, FLORIDA – Researchers from Hesperos and the University of Central Florida have developed a groundbreaking model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to better understand and combat Alzheimer’s disease (AD). Their research, published in Alzheimer’s and Dementia, aims to improve our understanding and treatment of the disease.
The NIH has awarded Hesperos Inc. a $2 million dollar research grant to develop an advanced, animal free platform to test the potency of Botulinum Toxin (BoT).
Hesperos Chief Scientist Dr. J Hickman was a featured speaker at Rare Disease Day at NIH discussing how Human-on-a-Chip systems are actively supporting therapeutic development for Rare Diseases. Watch his presentation here.
Development of an Overdose Model doi.org/10.1038/s41598-023-35694-4 Press Release Link to Publication This research provides an accurate way to model overdose in the lab, using human brain cells programmed to respond to many different opioids. Amid an … Read More